There are currently 2860 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
NCT06364410
Recruiting
This phase I trial tests the safety, side effects, and best dose of azenosertib in combination with trastuzumab deruxtecan in treating patients with HER2-positive and cyclin E amplified gastric or gastroesophageal junction cancer and other HER2-positive solid tumors that have spread to nearby tissue or lymph nodes (locally advanced), that have spread from where it first started (primary site) to other places in the body (metastatic), or that cannot be removed by surgery (unresectable). Azenosert... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastric Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm
Register for Updates
ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial
NCT06664879
Recruiting
To demonstrate the efficacy of targeted and tailored sequential therapy in patients with AML.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/05/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: AML
Register for Updates
A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
NCT05118789
Recruiting
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-520, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors. Phase 1 will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of NVL-520 in patients with advanced ROS1-positive solid tumors. Phase 2 will determine the objective response rate (ORR)... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/05/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
NCT06308588
Recruiting
To learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Philadelphia Chromosome-Positive, Acute Lymphoblastic Leukemia
Register for Updates
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
NCT06408168
Recruiting
To find out if the combination of repotrectinib and fulvestrant can control the disease in participants with metastatic invasive lobular carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma
Register for Updates
A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (EXPAND-1)
NCT06470763
Recruiting
The purpose of study ANV600-001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity and antitumor activity of ANV600 administered as a single agent or in combination with pembrolizumab in adult participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor
Register for Updates
Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
NCT06613217
Recruiting
This is a dose-finding study of oral zelenirstat (PCLX-001) in patients with R/R AML. There are two parts to the study: Dose Escalation and Dose Expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: MD Anderson Cancer Centre, Houston, Texas
Conditions: Relapsed Adult AML
Register for Updates
Psycho-Spiritual Management for Patients With Advanced Cancer and Their Family Caregivers
NCT06409065
Recruiting
The goal of this behavioral research study is to learn about the effects of two different supportive care programs on patients' and their family caregivers' psychological wellbeing and overall quality of life.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: MD Anderson, Houston, Texas
Conditions: Cancer
Register for Updates
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
NCT05890729
Recruiting
A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/05/2025
Locations: Xentria Investigative Site, Houston, Texas
Conditions: Pulmonary Sarcoidosis
Register for Updates
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
NCT06040099
Recruiting
The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/05/2025
Locations: Research Site, Houston, Texas
Conditions: Hepatocellular Carcinoma (HCC)
Register for Updates
Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
NCT06445907
Recruiting
To learn about the safety and tolerability of the drug combination of Q702, azacitidine, and venetoclax when given to participants with relapsed/refractory AML.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia
Register for Updates
A Study of XMT-1660 in Participants With Solid Tumors
NCT05377996
Recruiting
A Study of XMT-1660 in Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: MD Anderson, Houston, Texas
Conditions: Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
Register for Updates